Adjuvant Chemotherapy Improves Long-term Survival in Pathologic Stage III Rectal Mucinous Adenocarcinoma After Pre-operative Chemoradiotherapy

Overview

Journal Int J Colorectal Dis

Specialties Gastroenterology
General Surgery

Date 2023 Aug 5

PMID 37542591

Authors

Hualin Liao

Tao Li

Yahang Liang

Yaxiong Liu

Yuli Yuan

Mingming Li

Aidi Li

Yang Liu

Yao Yao

Taiyuan Li

Affiliations

Soon will be listed here.

Abstract

Purpose: The benefits of adjuvant chemotherapy remain debated rectal mucinous adenocarcinoma (MC). Our study aims to delve into the efficacy of adjuvant chemotherapy in pathologic stage III rectal MC by a large population-based database.

Methods: The Chi-square test was performed to examine the parameters between treatment groups. The overall survival (OS) and cancer-specific survival (CSS) of treatment groups were conducted by using the Kaplan-Meier method. The impact of factors on survival was assessed using Cox regression analyses. To balance the covariates and reduce the selection bias, we employed propensity score matching (PSM) to narrow the differences between treatment groups.

Results: The median follow-up time for overall patients was 80 months. In the pre-operative chemoradiotherapy (pre-CRT) group, patients who received adjuvant chemotherapy had significantly better 5-year OS and CSS. Multivariate analyses found that adjuvant chemotherapy was associated with better OS (p < 0.001, HR (95% CI): 0.66 (0.51-0.86)) and CSS (p = 0.012, HR (95% CI): 0.71 (0.54-0.93)). However, adjuvant chemotherapy was not an independent prognosis factor in both OS (p = 0.149, HR (95% CI): 0.76 (0.53-1.1); Supplement Table 1) and CSS (p = 0.183, HR (95% CI): 0.74 (0.48-1.15)) in patients who did not receive pre-CRT. After PSM, similar results were found in the pre-CRT and the no pre-CRT groups.

Conclusion: In conclusion, our population-based retrospective cohort study indicates that the effects of adjuvant chemotherapy were associated with the pre-CRT status in patients with stage III rectal MC. In patients who underwent pre-CRT, the receipt of adjuvant chemotherapy was associated with better survival outcomes. Conversely, adjuvant chemotherapy does not seem to confer significant survival benefits to patients without pre-CRT.

Citing Articles

The benefit of adjuvant chemotherapy in pathological T1-3N0M0 rectal mucinous adenocarcinoma: no improvement survival outcomes based on long-term survival analysis of large population data.

Liao H, Zeng T, Xie X, Li J, Li D, Yan K J Gastrointest Oncol. 2024; 15(4):1568-1579.

PMID: 39279951 PMC: 11399833. DOI: 10.21037/jgo-24-271.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Luo C, Cen S, Ding G, Wu W . Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019; 39(1):13. PMC: 6440160. DOI: 10.1186/s40880-019-0361-0. View

Orsini R, Verhoeven R, Lemmens V, Van Steenbergen L, de Hingh I, Nieuwenhuijzen G . Comparable survival for young rectal cancer patients, despite unfavourable morphology and more advanced-stage disease. Eur J Cancer. 2015; 51(13):1675-82. DOI: 10.1016/j.ejca.2015.06.005. View

Hugen N, Brown G, Glynne-Jones R, de Wilt J, Nagtegaal I . Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol. 2015; 13(6):361-9. DOI: 10.1038/nrclinonc.2015.140. View

Shin U, Yu C, Kim J, Kim T, Lim S, Yoon S . Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann Surg Oncol. 2011; 18(8):2232-9. DOI: 10.1245/s10434-011-1612-8. View

Hugen N, Verhoeven R, Radema S, de Hingh I, Pruijt J, Nagtegaal I . Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. Ann Oncol. 2013; 24(11):2819-24. DOI: 10.1093/annonc/mdt378. View

Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D . Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer. 2009; 100(6):881-7. PMC: 2661784. DOI: 10.1038/sj.bjc.6604955. View

Negri F, Wotherspoon A, Cunningham D, Norman A, Chong G, Ross P . Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol. 2005; 16(8):1305-10. DOI: 10.1093/annonc/mdi244. View

Pantel K, Alix-Panabieres C . Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010; 16(9):398-406. DOI: 10.1016/j.molmed.2010.07.001. View

10.

Gollins S, Moran B, Adams R, Cunningham C, Bach S, Myint A . Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Multidisciplinary Management. Colorectal Dis. 2017; 19 Suppl 1:37-66. DOI: 10.1111/codi.13705. View

11.

Denost Q, Fleming C, Burghgraef T, Celerier B, Geitenbeek R, Rullier E . An International Multicenter Prospective Study Evaluating the Long-term Oncological Impact of Adjuvant Chemotherapy in ypN+ Rectal Cancer. Ann Surg. 2022; 277(2):299-304. DOI: 10.1097/SLA.0000000000005742. View

12.

Naffouje S, Sabesan A, Powers B, Dessureault S, Sanchez J, Schell M . Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. Clin Colorectal Cancer. 2021; 20(3):e155-e164. DOI: 10.1016/j.clcc.2021.02.006. View

13.

Liao H, Zeng T, Xie X, Li J, Li D, KejinYan . Adjuvant chemotherapy does not improve cancer-specific survival for pathologic stage II/III rectal adenocarcinoma after neoadjuvant chemoradiotherapy and surgery: evidence based on long-term survival analysis from SEER data. Int J Colorectal Dis. 2023; 38(1):134. DOI: 10.1007/s00384-023-04428-3. View

14.

Carvalho C, Glynne-Jones R . Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncol. 2017; 18(6):e354-e363. DOI: 10.1016/S1470-2045(17)30346-7. View

15.

Bigness A, Imanirad I, Sahin I, Xie H, Frakes J, Hoffe S . Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation. CA Cancer J Clin. 2021; 71(3):198-208. DOI: 10.3322/caac.21661. View

16.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

17.

Zhang J, Xie X, Wu Z, Hu H, Cai Y, Li J . Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies. Clin Colorectal Cancer. 2021; 20(4):e240-e248. DOI: 10.1016/j.clcc.2021.06.004. View

18.

Vernmark K, Knutsen A, Loftas P, Sun X . The impact of adjuvant chemotherapy on survival in mucinous and non-mucinous rectal adenocarcinoma patients after TME surgery. PLoS One. 2023; 18(2):e0282211. PMC: 9970087. DOI: 10.1371/journal.pone.0282211. View

19.

Chand M, Rasheed S, Bhangu A, Stamp G, Swift R, Tekkis P . Adjuvant chemotherapy improves overall survival after TME surgery in mucinous carcinoma of the rectum. Eur J Surg Oncol. 2013; 40(2):240-5. DOI: 10.1016/j.ejso.2013.11.005. View

20.

Bhatia R, Gautam S, Cannon A, Thompson C, Hall B, Aithal A . Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metastasis Rev. 2019; 38(1-2):223-236. PMC: 6614013. DOI: 10.1007/s10555-018-09775-0. View